Why Veristat

Strengthening Our Impact with Growth and Expansion of Our Capabilities 

At Veristat, we champion innovation through the solutions we provide our clients across clinical trials and on specialized projects, supporting the success of therapies designed to extend, save and enrich lives. Over the years, we have strategically invested in organizations, people and resources to help our clients solve their most complex challenges.  

With our scientific strategies and a team unafraid of big thinking, we are passionate about helping you get your therapy to market–  and keep it there – quickly, safely and cost-effectively.   

HISTORY AND TIMELINE OF VERISTAT'S GROWTH

1994

1994

Veristat was founded by John and Barbara Balser, marking the start of a Clinical Research Organization (CRO) dedicated to solving the most difficult scientific and clinical challenges. 

2007

Veristat becomes a registered CDISC solutions provider, integral to our offering to ensure timely and compliant FDA submissions and reviews. 

2007

2011

Veristat adds Clinical Operations Services, expanding our ability to conduct clinical trials with the highest levels of scientific excellence, efficiency and results. 

2013

Patrick Flanagan joins as CEO to lead the company’s business strategy, organizational management and financial performance. 

2013

2016

Veristat expands into Europe with the acquisition of Spero Oncology and launches our Strategic Consulting Group

2018

Clinical Operations Services are strengthened with the acquisition of Topstone Clinical Research.  

Regulatory Services are established, foundational to Veristat’s core service offering. 

2018

2019

Operations expand into Asia with the opening of Veristat’s Taipei office.  
The acquisition of Catalyst strengthens North American capabilities in Regulatory Affairs

2020

Veristat’s acquisition of TCTC brings substantive capabilities and talent in Advanced Therapy solutions, furthering geographic reach into the UK and EU regions

 

The acquisition of Certus PV advances Veristat’s commitment to patient safety by adding post-market pharmacovigilance services.

 

Enhances patient-centricity offering by launching a flexible virtual clinical trial solution.

2020

2021

Veristat’s impact in Biometrics and European Regulatory is enhanced with the acquisitions of SQN Clinical and DDR


European footprint expands with the opening of our Barcelona office

2022

The acquisition of SFL adds commercialization capabilities, expands our EU footprint and diversifies our client base. 

 

Launches Strategic Resourcing/FSP solutions to build greater flexibility for sponsors.

 

Integrates Decentralized Clinical Trial (DCT) solutions into our clinical development full-service offerings

2022

2023

Expands Medical Writing team with the acquisition of European medical writing consultancy, Scinopsis 


Grows Biometrics capabilities and Asia footprint with the acquisition of Instat

2024

Ready to speak with the scientific-minded
experts who make the impossible possible?

LET'S TALK

Learn More with These Resources

Case Study

Advancing to Your Next Milestone – Global Regulatory ...

Case Study

Mastering a global approach to solving the complexities of ...

Case Study

Strategic Clinical Development Consulting